| HOME >> BIOLOGY >> TECHNOLOGY |
Payables to related parties 730 266
Social security and other taxes 227 153
Other current liabilities 2,701 1,433
5,826 2,815
Total liabilities 6,832 19,900
Total equity and liabilities 58,239 18,218
Consolidated cash flow statement
(In EUR x 1,000)
Year ended
31 December 2007 31 December 2006
(Unaudited) (Unaudited)
Cash flow from operating activities
Result before corporate income tax (14,935) (8,760)
Adjustments for:
- Depreciation 334 319
- Share-based payment expenses 1,143 159
- Gain on derecognition financial - 25
lease
- Re-purchase of EMT sales rights - 1,736
- Gain on deconsolidation AVP - (1,113)
- Changes in working capital 1,003 420
- Interest income/(expense) 275 789
Cash used in operations (12,180) (6,425)
Interest paid - (86)
Net cash generated from operating (12,180) (6,511)
activities
Cash flow from investing activities
Purchases of property, plant and (1,345) (387)
equipment
'/>"/>
| SOURCE Amsterdam Molecular Therapeutics B.V Copyright©2008 PR Newswire. All rights reserved |